Company Description
Vitro Biopharma is an innovative biotechnology company targeting autoimmune diseases and inflammatory disorders.
Through our proprietary platform, AlloRx Stem Cell therapy, we are developing novel cellular therapeutic candidates that are derived from culture-expanded mesenchymal stem cells (“MSCs”) sourced from the Wharton’s jelly of umbilical cords (“UCs”) donated by healthy volunteers following childbirth.
In the United States, we are authorized to conduct two clinical trials under two U.S. Food and Drug Administration Investigational New Drug applications to assess the safety and efficacy of AlloRx Stem Cell therapy in Pitt Hopkins syndrome (“PTHS”) and post-acute sequelae to SARs-CoV-2 (“PASC”), or long COVID, and expect to commence those trials in late 2022 or early 2023 following completion of this offering.
To date, over 300 subjects have received treatment with our AlloRx Stem Cells, primarily in foreign clinical studies conducted by third parties.
Our lead clinical program is expected to focus on PTHS, a rare neurogenetic disorder primarily affecting children that is characterized by global developmental delays including autistic features, language delays, intellectual disability, neuro-irritability and significant behavioral concerns.
We generate revenue from our other technologies through a number of other activities, including providing research services and through the sale of our stem cell products as well as cosmeceuticals through InfiniVive MD, our wholly-owned subsidiary, which helps to alleviate our capital expenses.
| Country | United States |
| Founded | 1986 |
| Industry | Health Care |
| Sector | Biotechnology |
| Employees | 12 |
| CEO | Christopher Furman |
Contact Details
Address: 3200 Cherry Creek Drive South, Suite 720 Denver, CO 80209 United States | |
| Phone | (855) 848-7627 |
| Website | vitrobiopharma.com |
Stock Details
| Ticker Symbol | VTRO |
| Exchange | NYSEAMERICAN |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0000793171 |
| Employer ID | 84-1012042 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher Furman | Chief Executive Officer, Director |
| Nathan Haas | Chief Financial Officer |
| James R. Musick | Chief Science Officer, Director |
| Caroline Mosessian | Chief Regulatory Officer, Chair of the Board |
| Tiana States | Chief Manufacturing Officer |
| Jack Zamora | Director |
| John Packs | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | 8-K | Current Report |
| Mar 14, 2024 | 10-Q | Quarterly Report |
| Feb 2, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 29, 2024 | 10-K | Annual Report |
| Jan 23, 2024 | 8-K | Current Report |
| Jan 16, 2024 | 8-K | Current Report |
| Dec 12, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 1, 2023 | D | Notice of Exempt Offering of Securities |
| Nov 22, 2023 | 8-K | Current Report |
| Aug 29, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |